BridgeBio Pharma Inc. (NASDAQ:BBIO)on Wednesday shared fresh clinical updates on infigratinib.

The company’s 52-week treatment with oral infigratinib in the PROPEL 3 study showed favorable trends versus placebo across exploratory endpoints that go beyond growth, including sleep apnea and otitis media (ear infection) events.

At 52 weeks, mean total apnea-hypopnea index (AHI) increased 10.4% from baseline with oral infigratinib, compared with a 49.2% increase with placebo.

Read Also: BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress

Among children younger than 8, AHI remained unchanged with infigratinib, compared with a 63.2% increase with placebo.

The estimated annualized rate of otitis media was 38% lower with oral infigratinib versus placebo, with the reduction reaching 47% among children younger than 8.

Body Composition and Fat Mass Metrics

Infigratinib was also associated with a smaller increase in BMI at 52 weeks (0.50 kg/m²) than placebo (0.93 kg/m²).

Lean body mass increased more with infigratinib (1.77 kg vs. 1.58 kg), while increases in body fat mass (0.95 kg vs. 1.12 kg) and visceral fat volume (1.55 mL vs. 18.42 mL) were smaller.

Commercial Potential and Regulatory Timelines

BridgeBio believes oral infigratinib is positioned to become the first and only approved oral therapy for children with achondroplasia.

The company submitted an FDA application for oral infigratinib in achondroplasia and anticipates a U.S. launch in mid-2027.

BridgeBio intends to submit a Marketing Authorization Application for achondroplasia to the European Medicines Agency in the fourth quarter of 2026. 

Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price forecast of $108.08. Recent analyst moves include:

  • HC Wainwright & Co.: Buy (Maintains Price Forecast at $120) (Sept. 2)
  • Mizuho: Outperform (Raises Price Forecast to $110) (Sept. 1)
  • Truist Securities: Buy (Raises Price Forecast to $107) (Aug. 12)

How BridgeBio Ranks On Momentum Versus The Market

Below is the Benzinga Edge scorecard for BridgeBio Pharma, highlighting its strengths and weaknesses compared to the broader market:

  • Momentum: Bullish (Score: 75.82) — The stock’s trend strength screens well versus the broader market, even if near-term momentum is cooling on the MACD signal.

The Verdict: BridgeBio Pharma’s Benzinga Edge signal reveals a momentum-driven profile.

With only Momentum available, read the setup as trend-following first—where holding the low-to-mid $70s matters for keeping the longer-term uptrend intact.

BBIO Stock Price Activity: BridgeBio Pharma shares were down 0.24% at $74.58 during premarket trading on Wednesday, according to Benzinga Pro data.

Read Also: Bitcoin-Gold Correlation Hits a 6-Year High: What's Going On?

Photo Courtesy: Billion Photos on Shutterstock.com